Table 4

Current hematological, cytogenetic, and molecular responses of surviving patients by therapy

ImatinibAllo-HSCTP
No. of surviving patients 39 38  
Median follow-up (range), mo 47 (25-108) 65 (18-108) .658 
CHR, no. (%) 36 (92.3) 38 (100) .240 
MCR, no. (%) 33 (84.6) 38 (100) .025 
CCR, no. (%) 33 (84.6) 38 (100) .025 
MMR, no. (%) 29 (74.4) 38 (100) .001 
CMR, no. (%) 16 (41.0) 37 (97.4) .000 
ImatinibAllo-HSCTP
No. of surviving patients 39 38  
Median follow-up (range), mo 47 (25-108) 65 (18-108) .658 
CHR, no. (%) 36 (92.3) 38 (100) .240 
MCR, no. (%) 33 (84.6) 38 (100) .025 
CCR, no. (%) 33 (84.6) 38 (100) .025 
MMR, no. (%) 29 (74.4) 38 (100) .001 
CMR, no. (%) 16 (41.0) 37 (97.4) .000 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal